Startup profile · funding coverage
Scribe Therapeutics
CRISPR-based genetic medicine platform spun out of Jennifer Doudna's lab.
Stage
growth
Status
private
Coverage
full
Why Scribe Therapeutics is interesting
Industrialized CRISPR enzyme engineering for in vivo therapies — a16z-led Series A before Biogen partnership headlines.
Key facts
- Series A (Oct 2020): $20M led by a16z (a16z announcement, Businesswire)
- Biogen collaboration on neurodegeneration programs (company press)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Investors in our directory
Funds linked from Scribe Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Scribe Therapeutics's financing or category context.
Last updated: 2026-07-24